About Cyteir Therapeutics Inc
Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing precision oncology medicines that inhibit deoxyribonucleic acid (DNA) damage repair and cause cancer cell death through a therapeutic strategy known as synthetic lethality. The Company's pipeline includes CYT-0851 and CYT-1853. Its lead program, CYT-0851, is an oral, once-daily, small molecule inhibitor of RAD51-mediated homologous recombination (HR), a DNA repair pathway critical for the survival of some cancers. The Company is developing CYT-1853 as an inhibitor of RAD51-mediated HR.